UBS Global Biopharma Conference - MEREO BIOPHARMA GROUP PLC
Thank you, everyone, for joining us for our inaugural UBS Global Biopharma Conference. My name is Jun Lee, one of the biotech analysts at UBS. And for this session, we have Emil Kakis, CEO of Ultragenyx, and CFO of Ultrogenyx as well. Thank you. Emil, thanks for spending time with us. For the audience who may be new to the story, could you spend a few minutes describing the focus of the company and the recent updates and why investors should pay attention to Ultragenx now? Thanks, Jun. Thanks for having us. And Howard, I, and the whole Ultranetics team are happy to be here. Ultranetics is a company that's been on the public markets since 2014. We're a rare and ultra-rare company with six approved products in those 12 years on the market, heading toward a billion in revenue next year. And we expect to be profitable next year, meaningful profitability achieved. We've been working in a wide variety of types of drugs, gene therapies, biologics like antibodies or enzymes, and small molecules as well. We're agnostic as to mode and focusing on the best possible treatment strategy. We had two misses this year that have been a challenge for the stock, including the Osteogenesis Imperfecta since the Truth of Math program, as well as in the Angelman program. Between the two, the OI since the truth of math program, we think, has great data that we're going to continue to pursue. We can talk more about that at some point. The Angelman Program, we have to set aside at this point. And because of that, we've implemented important cost-cutting, approximately 20% of our staff, and reduced R&D spend by 50%. I'm sure Howard can talk more about what we did. But the point where the meaningful cost reduction to put us on path to be profitable, full-year gap profitability next year, and put us in charge of our future. In addition, we sold two PRVs, which added about $350 million to the balance sheet, giving us more than $700 million in cash. We are a balance sheet that's full, and we should be adding Gramella Cash over the coming year. So we're in a very good situation from the standpoint of profitability, but we did have two big catalyst myths put us where we are today. We think we're going to turn that corner and move forward with the continued growth of our base business, plus the tuned gene therapy launches, which are doing well, and the continued pipeline focus on a narrower, tighter footprint of high-value programs, programs, which includes the Choose a Man for OI, as well as our OTC program and an early stage program. But we're encouraged by where we're at, but we certainly have had two hits that have put us in a more difficult place. But I'm confident in the future and our ability to be profitable and generate meaningful R&D value, as Well as commercial value going forward. So as Emil said, you know, you've undertaken some really difficult but major reductions in a goal towards profitability, what are some pushes and pulls into your profitability assumptions? And once you achieve that profitability in 2027, how sustainable is that going forward? I think, Howard, do you want to answer that one? We project profitability in 27, and we've said we intend to sustain it. The assumptions that get us there, we have a base business of four programs that's been growing north of 20% since we've gone commercial. And And then we have the two gene therapy launches that we're in the process of now, and I think we'll probably come back to some more detail on those. But that gives you a growth rate on the top line, where we can control our spend on R&D and SG&A. We gave some guidance on that on our last call. We will keep R&d next year under $350 million, and we'll keep SG&a under $375 million. And those facts get us to profitability. And importantly, as Emil mentioned, we now have the balance sheet strength to not need to raise to get the profitability so that's a pretty big corner to turn as a biotech to be able to say all of that in one year's time and what proportion of the you know the remaining head count is focused on r&d versus hna you don't put that out yeah i don't i don' t know that we've guided directly to that um i think most of our costs as in most companies are are people-based right a large percentage of them um but we think look ultimately what we think is that the r&ds that we've guided to, can support the commercial programs because there's still some R&D that goes on there, plus a very focused base of spend on R&B and the UX143 program and 016 and the 301 programs. That's really the core of it. And then our SG&A is meant to support the six programs we have on market globally. And does the R&V spend take into account the potential new trial of, you know, setuzumab and osteogenesis imperfecta, which we'll get into in a little bit. Yeah, it absolutely does. It does. Yeah, we do not have to change our guidance at all for that. And how much of the new launches need to be contributing to 2027 revenue to maintain your profitability guidance and sustainability of that profitability? Yeah, so with new launches, we don't tend to give that guidance for a little while just to see how they uptake and whatnot. But if you look at the trends from our four current programs and apply sort of a normal growth rate to that, it's not a very big burden of add that you'd need from the two gene therapies. And, you know, before we move on to the two recent launches, congratulations on Genglycos and Fayuvi. from the existing commercial base of drugs, what do you expect in terms of growth of your core franchise, including Chris Vita and Mepsevi and Dojovi? Yeah, so again, we haven't guided to that. But historically, we've grown north of 20%. Last year was our slowest growing year, and it was 20%. Got it. It's been four, five, six years now, I think, of 20% growth. So we've been very good. You know, that growth is based on several things. One is, of course, the population growing, but I think we're adding new territories, including, for example, Japan, which had FKESA growth the year before. This year is launching Dojolvi. We've added Middle East. Middle East and Dojoli is doing extremely well. A lot of patients in the Middle East are being added through name patient, and now we've actually filed the follow-up there. So as we build the territory, we're continuing to grow. So within established areas, the growth may be slower, but with the added territories I think that's really continued to improve and maintain that growth rate, which has, I think, been exceptional performance by the commercial team, the entire team working to do that. But that global franchise now is set up to be able to take on two new products in the same inborn error space and to be a launch. So we can leverage that investment now and put new products in it. And that's wirklich what's going to be special about our ability to grow revenue and gain leverage commercially. and Chris Siva of the base business Chris Vita is a very important drug doing about 5 to 5 20 million per year the composition of matter patent is up for I guess exploration in 2032 ish what is your life cycle management strategy and when do you need to start planning for that well Keo Karen and ourselves have been talking about it for a while and the first thing I say about rare, ultra-rare disease biologics is they don't really have loss of exclusivity and a decline in revenue like some other product areas. A lot of those programs maintain themselves, but we still have to plan for it, and we have to protect for it. But I would not look at that as a precipitous cliff as it can be for other disease areas, partly for how they're commercialized through specialty pharmacies and individual contracts. So with regard to LOE planning, Kilkerian has done some work. We have done some works on next-gen versions of Chris Vita. They already started in the clinic with our agreement. We have a non-compete with them, and so the plan is to collaborate on how we do these things. They have a couple molecules. We have one. We have another molecule as well. And we'll come up with our plan to put this in play and be able to launch the next-generation version. our goal with the next gen version would be to have some improvement, not just a version but a version that has real property improvement it's a challenge to make it more better because actually Chris Vita is like a second generation product out the gate it's fully bioavailable subcutaneously and it has no anti-drug antibody or hypersensitivity reaction, so it's a very clean profile, it's a very good drug, so we want to make it better while keeping those properties of an excellent drug, it is possible we look to maybe improve potency to some degree, and we look at maybe extending the time. But these are factors we'd want to have, a product that really was better. And we're going to work together with Karen on that problem. So we expect by the time LOE is happening, we already will have a next-gen version of CRIS-FETA. Looking forward to that. You know, I know you mentioned a couple of misses in recent times, but overall, your hit rates are pretty high, and you have two approvals. People don't talk about it as much, But overall, you have a pretty high hit rate because you're targeting diseases with well-known targets or drivers of diseases. And your FiUV and GenGlycols are examples of that. For both, you know, what are the launch looking like so far? And how many patients have you identified that may be ready to be dosed and all that stuff? so so far both products are doing well and we're pleased with what we're seeing in launch we won't put out specific numbers until we get to early in january we'll we'll put out how many qualified treatment centers are how many start forms we have and what the revenue was in the in the at the end of this year but so far things are going well we're encouraged by what we've seen i think for uv is a more urgent and so we certainly have been more immediate and rapid interest because parents are rapidly interested, not just the U.S., but globally interested in getting treated. So that's been a sign I expected, but not everyone did. But I know the San Felipe community really well, and I was pretty sure their parents would be calling us or calling their doctors and, you know, driving to get treated. So both are doing well from the standpoint of the number of patients out there. In San Felipe, it's around 3,000 to 5,000 in the commercially accessible world, and for the other program, it's maybe around 6,000, about a fourth of them, right, are expected to be U.S. Within the San Felipe population, there may be some patients that are, let's say, bedridden at the end of life because they spend 5 to 10 years at the ends of their lives. That stayed probably not within the label which says preserve neurodevelopmental function. That's not specific in the label, but I would expect those patients not to be. We certainly are aware of something on the order of 300 or 400 U.S. patients that are potentially treatable. And for GSD1A, it's on the order of 1,600, a couple thousand, depending on which way you look at it, are available. We'd expect GSD 1 to take a little more time. It's urgent, but not quite as crisis urgent as Safayouvi is. But we expect it to continue to build and we expect both programs to do well. when would you be in a position to share things like start forms scheduled infusions and more concrete metrics of the launch we'll be doing that in january okay and we'll normally do that at the beginning of the year at a competitor conference yes and the but we won't be putting out forecasts for the new products until we have about six quarters of experience That has been our standard we set from all of our launches. We wait six quarters to get a feel for it. And for GeneThread particularly, I think it's important too. But we'll be able to give you start forms as well as reimbursed patients and revenue at that time. And we'll probably provide overall numbers for the coming year, which we have in the past, but we won't provide specific forecast for those two new products. But we will provide them for the other programs. That's fair enough. I know you've invested heavily in the manufacturing capacity of AAVs in the Massachusetts area. Tell us a little bit about that and what that implies. How many patients can you dose with the capacity that you have? Well, in our view, if you're going to be in the AAV space, you really should try to invest in manufacturing capacity because it's a relatively high-cost, high-complexity situation, and I think it's far more cost-effective and more adaptable to manage yourself. So we have done that. We do have a partner for the PhiUV drug substance in Andolin, and we do the fill-finish and the manufacturing for gen glycos. And we would expect to be putting other gene therapy programs in the plant. I can't tell you any specific on how many patients we can treat out of the plant because it really depends on which product and how many runs we run. The plant is operating one of the suites right now. We have a second suite that's there that's not outfitted but gives us capacity to increase. So if we were using up the capacity, we could implement and outfit the second suite's already built. It's there. So we could expand capacity without having to do another plant, right? We designed it that way, and we'd set it up to run one and then add the other without... There is some cost to it, but it's not like building another plant. So I think we've been pretty smart about how to do it the right way. The plant now, fully inspected and approved for producing both the products. Excellent. Now, let's get into pipeline. CitrusMap for osteogenesis imperfecta looks like there's real signal based on the post-hoc data. How much of that was pre-specified or how much of dat was just trying to do post-mortem and finding a signal? Yeah, so if you look at the bone marrow density data, that, which hit a p-value of 0.01, was about one z-score increase in bone marrow density, which is about like a 30% increase in the young patients. That's a profound effect. So that's very statistically significant pre-hoc, post-hock, any way you want to do it. But it was a very profound effect, and that's what this drug is doing for these patients, dramatic improvement of bone marrow density. It also was successful head-to-head against bisphosphonates in the second study. Yeah, shocking. It beat both. Yeah. So it's clearly better than what everyone is using routinely now for that effect in the BMD. And that's all without any post-hoc analysis. Those were the original analyses. We also found among the tertiary endpoints in the orbit study, which was placebo-controlled, there were two different pain endpoints and two different physical functioning. Most of those were statistically significant, nominally significant, or a strong trend in pain and physical functioning as well. And those were tertiary, because usually those are hard to hit, but we actually hit them in tertiary. So the thing we missed in the study was the fracture AFR. And the fracture afr, we missed an orbit because the fracture rate was just too low. We had an entry curve of at least one, and we stratified by above or below three. And what we ended up with is an average around 0.55. and the median in the placebo group was zero. So this, unfortunately, left us not a lot of room to gain. Now, what we announced at the post-hoc was looking at the strat I just mentioned, above and below three. If you look at the above three group in those patients, you see a meaningful effect. And so if you look a little bit more closely at that study and you look at the other study, the COSMIC study, in the high fracture patients, you see meaningful 40% to 60% reduction in fractures, which is kind of what we were expecting to see in the study from the beginning so our biggest problem was we didn't enroll in orbit of high fracture patients and the other feature which was true in the cosmic study is that the the bones that were not long bones improved very dramatically like clinical fractures of the vertebral column were reduced 94 percent went from 18 fractures in one group to one in the other treated group and the verbal column is extremely important in oi is why patients end up with these collapsed spines and in wheelchairs right so it's life-changing so that is a very strong effect and that bmd effect on the spine is why that's happening the long bones were not as well affected but a lot of those patients have bent long bones and they already have metal rods in them right so they're they're kind of structurally unsound and so the patients were feeling better and we think we're just running around there and having more of those effects but these are complexity. Sometimes you learn about this in the middle of a trial in OI, and we've learned some things from that. But I think the fundamental truth is they have extremely low BMD. We have a dramatic effect on BMD, even head-to-head against active. And that effect will improve fractures, particularly bones that are able to gain bone marrow density quickly, and that there is a pain physical functioning effect that's important to patients. So this is a drug that really does work in these patients, and it's worth fighting for. We're talking to FDA about what that means, and we have said that there are some prospective data that may be required. We're working through what that mean. And what I want to say is we're committed to figuring out one way or another. Now, we've built into our plan as if we're running another trial. We're continuing to have our discussions. We've had a couple meetings with FDA, but these processes take time. They're not instant. It's not something that gets solved in one meeting. It takes some time to work through a new situation. And we as a company have done that multiple times. We've been involved in a lot of regulatory discussions. The FIEVI approval was an example of one of a couple years of discussions on biomarker endpoints. We included the whole industry in that discussion, you may remember, in the battle over a biomarkER. But in the end, FDA did agree, and we got them there, but it did take a little time. There's a lot to unpack there. Number one, was, so again, remind me, so the three or more baseline fracture rate analysis, was that a pre-specified or no? We pre-specificed the strata of above and below three for randomization. Okay. Okay, so that strata was known to us. Got it, got it. That it would matter. Yes. But we didn't specify the subset for the statistical analysis post hoc in that sense, right? Understood. and um now there are different subtypes within oi type 1 3 4 i believe one of them is just both alleles are mutant and one of em is like heterozygous or something tell was there a signal in one subtype versus the other right all three subtytes have bone deficiency although it's worse than threes and the worst and threes yeah worse however all three respond with improvement of bone marrow density, and all have a response in bone. So it's not a differentiation, but there is a differentiation in the type 3s and 4s have more deformed long bones, which may make a difference in how well they can heal. You can't change the structure of a bone. Just laying more bone on a weird curved bone is not going to solve the structural problem that exists. So that's the difference. In orbit, it turned out we had twice as many 3s, the most severe ones, in the trisomab group. and it was type 4s in the other. So that was an odd T. We did not expect that was probably hurt the study to some degree. We thought the study was large enough not to have to worry about it. So that is one difference. But all the groups' types respond. So in the OI type 1, they have a deficiency of collagen. They are not homozygous, but they have a deficiency in collagen. In type 3s and 4s, they have an abnormal collagen. Not as null, but abnormal. The normal collagen disrupts the cells formation of collagen also disrupts cell biology but the thing is people felt is that the collagen was causing the bone to be weak directly like the structure of the collagen but the truth is that whether it's deficiency or structure of collagen there's an impact on bone regulation what that means is the cells the bones are resorbing their bone more and making less bone the net effect is that you have very severe bone mineral density deficiency, less bone and while there may be a structural effect of the bone strength, they don't have enough bone the reason that's important is that the truth map is going to make more bone and therefore in animal models with mutant collagen and you make more bone, that you can normalize bone mineral intensity and you actually get normal bone strength even with an abnormal collagen so the truth is the bone regulation effect of the disease is more of the problem than it is the weakness of the collagen fiber so that helps a lot it seems like it works across different subtypes and we'll see what the fda says but you know um i mean lay out some scenario a b and c for us you know like it could either they say okay i submit based on existing data it's high on metanyl nothing's available and do a confirmatory trial or do a prospective trial and have that enrolled to a certain level and we'll take a look at it or just do a complete placebo-controlled trial all over again with the learnings from ORBIT and COSMIC. Yeah, those are the range of options. We think we have a lot of data in hand, if you focus on BMD. The BMD has not been accepted as a predictive biomarker by FDA for OI, But it has been accepted as a validated surrogate marker for osteoporosis. Sure. Now, the truth is both programs are both tight, so the osteoporous and osteogenesis perfecta are different. They both have the common ground of BMD deficiency. So if one validated, you think it should be accepted. Right now it's not, right? So that's part of what the discussion would be is how predictive is BMD in OI. But it's right now not accepted as surrogated. the focus has been on fractures. So it's hard for us to pick the scenarios, but you could have a new trial required, some prospective new trial. We have also crossover data from the existing patients being treated. There's other set of data and this discussion about the endpoints and what is clinical benefit in OI. Is there certain bones only that have benefit or is it a broader view of what constitutes clinical benefit? So these are some of the discussions we're having. I don't want to go into more detail because I don' think it's productive. The question that people ask is, well, should they assume another trial is being conducted? And if you did that, how does that affect your financials? Yeah. And what we've said is that in our budget for next year, we're already including the fact that another trial could be conducted. So if we do another trial, it is included already in the numbers. It doesn't impact our plan. All right. That already is built in. That was a built in assumption. Now, is that trial prospective or is it a post-confirmatory requirement? That would be a question. But I think people should not assume that that trial is post-marketing. I don't think you should assume that is the base case right now. I don' t want to set that expectation. I would say we probably have to have some trial data in order to get approved. However, we certainly are looking at the possibilities of trying to do something less than that. I mean, a trial of COSMIC size and inclusion-exclusion could work if you made the entry criteria a certain way and in a high fracture rate background. The COSMEC was only 69 patients, so certainly a larger COSMET trial is a little easier to do. The reason it's easier to use, the placebo-controlled trial, the difficulty was, And the reason why we had lower fracture severity is the doctors don't want to put patients in a trial that could be one to two years and take them off their bisphosphonate, right? Because that means they're going to get worse. So they didn't put their sickest patients in, even though we told them to. They ended up told us afterward, well, they didn'T want to Put the sickest ones in, which is what they needed to do. Because they don'T want To put their kids on withdrawal from the treatment that does help them right now for two years, up to two Years, right, that was a big hurt. so that was a factor if we do another trial would probably be more like a cosmic-like trial because therefore we could have a higher fracture patients we're doing a head-to-head against active um but that would be the more the type of design you could do and would also be better for patients standpoint that they're not placebo controlled and therefore they're not being denied treatment and it's also trial you could do more readily in the post-marketing setting too right obviously because no one's being denied treatment, right? So there's many features why that makes more sense. When do you think you'll be able to provide an update from the FDA after all the back and forth? Well, as soon as the FDA gives us what we want. The FDA negotiation is, first of all, they've been collaborative. They are interested in the indication. And the group that's there has been there a while. That group has been there also and worked with us on CRISFIDA, the same people. They haven't turned over, just to be clear, because a lot has turned over to FDA, but not that group. So this is good. There are people that know us, know what work we do, the quality of the work, and are having a professional and thoughtful discussion with us. So this ist good. We want to try to move the field forward, and I just can't tell you a predictive number. I know people want to answer immediately, but we're trying to move the field forward and change how we look at this disease. And I think we're making progress. We've had meetings, there may be others. But the idea that you do one meeting and everything's solved, that's a very simplest way of the way reg works. It usually is more involved. And FiUV on heparin sulfate was over a two-year period. Now, I don't say we're going to take two years. I'm just saying it's kind of what can be at times. now the FDA is a lot more stable than it has been which is good and I think that the senior team there is very angled toward trying to help rare disease programs that's the rare disease framework they're talking about it they want to and we have connections to them so we think there's a good discussion to be had here on here's a Good example of a situation that I think could benefit and in in fact, probably needs to benefit from FDA thoughtfulness on how to approve a product for a rare disease like OI. I mean, the head of CBER has turned over. Does that make a difference for you guys? Well, I'm just saying the prior CBER head wanted a placebo for a lot of other things. The new people, I think, are very rational and thoughtful. They're respectful reviewers, but also willing to engage. So I think they actually have the right attitude and approach, and we're pleased to work with them, and we did with Fiuvi and Genglycos, both programs with the CBER head. The CEDAR head we know less about, but I think the team there has been more stable than the CBR team, which has turned over a lot. Look, I think we're encouraged by where the FDA is going. I think they're going the right way. Things are stabilizing. They're starting to fill in. And I would say there's professional, rational thinking going on, so that's good. We can go over a few more minutes. but we have to talk about DTX 401 for OTC you already reported oh sorry, 401 is approved yes, sorry, 301 for OPC you already recorded very strong data from the blind portion of data study phase 3 enhanced trial what are you trying to achieve from the open label portion yes the blinded portion is really the important one, that showed excellent ammonia control, but more importantly with just ammonia control, it talked about their brains getting clear. The PGI-SKI, the Global Impression Skill Scores, showed 89% plus two plus three. That means much better or very much better. 75% were plus three, that is very much better, versus 0% placebo. So even though these patients were stably on meds for OTC, standard of care, they felt much better, but that's what the difference in having the gene therapy is that they get the actual enzyme and they control ammonia tightly. So that's what's important. What I would say to you is that really should be approvable, that alone. What we're looking at in the open label session is the ability to remove the current care and have the patient still be sustained. The challenge of removing care, that patients are reluctant to remove care, like drugs, because that's been their security blanket, plus a lot of them are not used to eating protein, to move quickly off completely is a big faith. And a lot of these late-onset types, by the way, were discovered, they hadn't been doing any diet or drugs, and they're 12 years old, let's say, and they have a cold, and they end up in the ICU under a coma. So when they have events, it's not like they get a little sick. They'll end up In the ICU and could die. So if you could tell them, yeah, why don't you take away these security blanket drugs that have saved you, and trust that everything's going to be fine. I mean, it takes a little time. Doing it in a blinded field, which was FDA asked for, was not possible. So what we're looking for is to see if we can get a fraction of the patient off their drugs and diet completely. And we'll see. But there is a sociologic aspect to this, which is getting people comfortable that they can go naked without any of these things. And it's not like you know instantly if something's wrong. You may be fine and then have a crash. So that's why they're afraid of it. But we're working through it. we expect to be able to have that. By 64, we need to get a certain fraction of patients off the drug's diet. But I would say to you, the data we have on hand show the drug is valuable and should get approved. And ammonia is already accepted, in fact, a validated endpoint for FDA for approval. And we've shown, on average, we improved to normal range, but even the sixth patients got to normal range. And we think that shows you that we can control ammonia far better than you can with current standard pair. I'm looking forward to this getting approved because, based on our conversations with doctors at these genetic medicine conferences, this seems like a much bigger TAM, relatively speaking, and much more patients are more like 5UV. On that need, it's much more greater. That's great. One of the really interesting things, though, is some of the CP patients think they were fine, even the ones in our study. but they find out what it is to have really good pneumonia control exactly they say i'm way better but you said you were fine now you're way better because they didn't even know what fine was they don't know that what we feel like when your brain is clear they have never had that before so they don' know what feeling good feels like but after they go i'm really feeling clear my brain it's they don never have that feeling so it's it's kind of exciting when they realize i wasn't fine now i'm fine okay but if you don't now when you've been sick your whole life it's It's hard to know. But that's why that PJC data is so compelling, so dramatically better, when everyone said they were fine. So I've had people tell me, well, they're fine. They said so. The doctor said so, but then why are they feeling so much better? So it's one of the things we learn in rare when you're chronically ill. You don't know what good is until you get it. I mean, I could go on and on, but I think we're out of time. Emil and Howard, thank you so much for your time.
- Company
- MEREO BIOPHARMA GROUP PLC
- Keywords
- MEREO BIOPHARMA GROUP PLC